Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Nov 23:12:800609.
doi: 10.3389/fimmu.2021.800609. eCollection 2021.

Commentary: Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid

Si-Hang Wang  1 , Ya-Gang Zuo  1
Affiliations
Comment

Commentary: Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid

Si-Hang Wang et al. Front Immunol. .
No abstract available

Keywords: IL-13; IL-4; bullous pemphigoid; dupilumab; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Direct and indirect activities of dupilumab in the immunopathogenesis of BP. BP, bullous pemphigoid; IL, interleukin; Th2, type 2 T helper; Ig, immunoglobin.
See this image and copyright information in PMC

Comment on

References

    1. Venning VA, Taghipour K, Mohd Mustapa MF, Highet AS, Kirtschig G. British Association of Dermatologists' Guidelines for the Management of Bullous Pemphigoid 2012. Br J Dermatol (2012) 167(6):1200–14. doi: 10.1111/bjd.12072 - DOI - PubMed
    1. Ge XL, Li SZ, Jin X, Jin HZ, Zuo YG. Treatment of Bullous Pemphigoid in Chinese Patients With Tripterygium Wilfordii Hook F. Dermatol Ther (2020) 33(4):e13721. doi: 10.1111/dth.13721 - DOI - PubMed
    1. Zhou T, Peng B, Geng S. Emerging Biomarkers and Therapeutic Strategies for Refractory Bullous Pemphigoid. Front Immunol (2021) 12:718073. doi: 10.3389/fimmu.2021.718073 - DOI - PMC - PubMed
    1. Zhang Y, Xu Q, Chen L, Chen J, Zhang J, Zou Y, et al. Efficacy and Safety of Dupilumab in Moderate-To-Severe Bullous Pemphigoid. Front Immunol (2021) 12:738907. doi: 10.3389/fimmu.2021.738907 - DOI - PMC - PubMed
    1. Zhang J, Fang H, Shen S, Dang E, Li Q, Qiao P, et al. Identification of Immunodominant Th2-Cell Epitopes in Chinese Patients With Bullous Pemphigoid. J Invest Dermatol (2018) 138(9):1917–24. doi: 10.1016/j.jid.2018.03.1515 - DOI - PubMed

Publication types

MeSH terms

Substances